RT Journal Article
SR Electronic
T1 Comparison of severe and non-severe COVID-19 pneumonia: review and meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.04.20030965
DO 10.1101/2020.03.04.20030965
A1 Ji, Weiping
A1 Zhang, Jing
A1 Bishnu, Gautam
A1 Du, Xudong
A1 Chen, Xinxin
A1 Xu, Hui
A1 Guo, Xiaoling
A1 Cai, Zhenzhai
A1 Shen, Xian
YR 2020
UL http://medrxiv.org/content/early/2020/03/09/2020.03.04.20030965.abstract
AB Objective To compare the difference between severe and non-severe COVID-19 pneumonia and figure out the potential symptoms lead to severity.Methods Articles from PubMed, Embase, Cochrane database, and google up-to 24 February 2020 were systematically reviewed. Eighteen Literatures were identified with cases of COVID-19 pneumonia. The extracted data includes clinical symptoms, age, gender, sample size and region et al were systematic reviewed and meta analyzed.Results 14 eligible studies including 1,424 patients were analyzed. Symptoms like fever (89.2%), cough (67.2%), fatigue (43.6%) were common, dizziness, hemoptysis, abdominal pain and conjunctival congestion/conjunctivitis were rare. Polypnea/dyspnea in severe patients were significantly higher than non-severe (42.7% vs.16.3%, P<0.0001). Fever and diarrhea were higher in severe patients(p=0.0374and0.0267). Further meta-analysis showed incidence of fever(OR1.70,95%CI 1.01-2.87), polypnea/dyspnea(OR3.53, 95%CI 1.95-6.38) and diarrhea(OR1.80,95%CI 1.06-3.03) was higher in severe patients, which meant the severe risk of patients with fever, polypnea/dyspnea, diarrhea were 1.70, 3.53, 1.80 times higher than those with no corresponding symptoms.Conclusions Fever, cough and fatigue are common symptoms in COVID-19 pneumonia. Compared with non-severe patients, the symptoms as fever, polypnea/dyspnea and diarrhea are potential symptoms lead to severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo Funding supported the projectAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript was obtained from online databases. https://www.ncbi.nlm.nih.gov/pubmed http://www.webofscience.com http://www.clinicalkey.com